[{"address1": "20 Acorn Park Drive", "city": "Cambridge", "state": "MA", "zip": "02140", "country": "United States", "phone": "617 949 4360", "website": "https://omegatherapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 93, "companyOfficers": [{"maxAge": 1, "name": "Mr. Mahesh  Karande", "age": 49, "title": "President, CEO & Board Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 910387, "exercisedValue": 0, "unexercisedValue": 2979079}, {"maxAge": 1, "name": "Dr. David A. Berry M.D., Ph.D.", "age": 45, "title": "Founder", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 20331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara Y. Chan", "age": 59, "title": "Principal Financial Office, Principal Accounting Officer & Chief Accounting Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Eva  Stroynowski", "title": "Senior Vice President of Investor Relations & Corporate Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Mullin", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  O'Donnell Ph.D.", "title": "VP and Head of Computational Genomics & Data Sciences", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kaan  Certel Ph.D.", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisamarie  Fahy", "title": "Senior Vice President of Clinical Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jennifer  Nelson Ph.D.", "title": "Senior Vice President of Research", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.38, "open": 1.37, "dayLow": 1.33, "dayHigh": 1.4, "regularMarketPreviousClose": 1.38, "regularMarketOpen": 1.37, "regularMarketDayLow": 1.33, "regularMarketDayHigh": 1.4, "beta": 1.864, "forwardPE": -1.4945055, "volume": 98205, "regularMarketVolume": 98205, "averageVolume": 381337, "averageVolume10days": 99280, "averageDailyVolume10Day": 99280, "bid": 1.33, "ask": 1.4, "bidSize": 100, "askSize": 100, "marketCap": 75010800, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 6.3, "priceToSalesTrailing12Months": 11.880076, "fiftyDayAverage": 1.7491, "twoHundredDayAverage": 2.652525, "currency": "USD", "enterpriseValue": 157210880, "floatShares": 21329536, "sharesOutstanding": 55155000, "sharesShort": 5610043, "sharesShortPriorMonth": 5342902, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1017, "heldPercentInsiders": 0.01622, "heldPercentInstitutions": 0.93954, "shortRatio": 20.64, "shortPercentOfFloat": 0.2928, "bookValue": 0.476, "priceToBook": 2.857143, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -78896000, "trailingEps": -1.42, "forwardEps": -0.91, "enterpriseToRevenue": 24.899, "enterpriseToEbitda": -1.993, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "OMGA", "underlyingSymbol": "OMGA", "shortName": "Omega Therapeutics, Inc.", "longName": "Omega Therapeutics, Inc.", "firstTradeDateEpochUtc": 1627651800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e046328d-569d-31a8-8bc4-add6aa7b1218", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.36, "targetHighPrice": 15.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.14, "targetMedianPrice": 12.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 45852000, "totalCashPerShare": 0.831, "ebitda": -78886000, "totalDebt": 126949000, "quickRatio": 1.825, "currentRatio": 2.195, "totalRevenue": 6314000, "debtToEquity": 483.394, "revenuePerShare": 0.114, "returnOnAssets": -0.25373, "returnOnEquity": -1.2914599, "freeCashflow": -41808876, "operatingCashflow": -64604000, "revenueGrowth": 1.812, "operatingMargins": -7.76945, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]